&lt;i&gt;SYTL4&lt;/i&gt; May Serve as a New Predictive Biomarker for Survival and Trastuzumab Treatment Responsiveness in HER2-Positive Breast Cancer. The gene discussed is ERBB2; the disease is breast cancer.